Biomedical subjects

H Hirschberg

Publications and source records attributed to H Hirschberg.

At least 37 records · Page 2Linked to original sources

PubMed1996

Fractionated stereotactic radiation therapy for intracranial arteriovenous malformations.

Fractionation of radiotherapy is a radiobiological advantage because the radiation effects on healthy brain tissue are reduced. We used fractionated stereotactic radiotherapy for cerebral arteriovenous malformations employing a modified linear accelerator and a noninvasive stereoadaptor. The treatment was given in two sessions (1,400 cGy x 2). Control angiography at least 2 years after treatment was performed on 20 patients. The malformation was completely eliminated in 14 of 15 patients with small arteriovenous malformations. None of the 5 patients with large malformations had their lesion eliminated, but in 4 the malformation was significantly reduced. Fractionated stereotactic radiation therapy using a conventional accelerator is an effective and safe technique in the treatment of intracranial arteriovenous malformations and compares favorably to radiosurgery.

Adolescent↗

PubMed1996

Implementation of a stereotactic microscope using an optically coupled tracking system.

Image-directed neurosurgical systems allow the correlation of a point in the operative field to a corresponding point on the patient's CT/MR scans. We have modified a surgical microscope by mounting three light-emitting diodes (LEDs) on a small frame attached to the microscope. The operative field was registered to the MR scans by indexing four MR/patient visible fiducial points with a LED pointing device. To calibrate the microscope, the probe point was focused and centered in the microscopic field of view with the aid of cross hairs in the microscope ocular. The focal plane of the microscope could now be tracked in addition to the probe tip. During surgery the point of interest is centered in the cross hairs and brought into focus, and the corresponding point is indicated in three planar views on MR scans.

Brain Neoplasms↗

PubMed1993

Long-term results after percutaneous retrogasserian glycerol rhizotomy in patients with trigeminal neuralgia.

We have evaluated the long-term results of percutaneous retrogasserian glycerol rhizotomy (PRGR) in 60 patients with classical trigeminal neuralgia. Complete initial pain relief was achieved in 93% of the patients. Numbness was initially reported by 3/4 of the patients and at follow-up by 1/3, while long-lasting dysaesthesias were an important side effect in 38% of previously untreated patients. The half-life of the method was 47 months in our material, and this figure compares favourably with other previously reported series. The method carries a significant risk of long-lasting and troublesome sensory disturbances. Another disadvantage of the method, reported in the present long-term study, was the high incidence of recurrent neuralgia. We are unable to identify predictors of recurrent neuralgia after PRGR, although major recurrences were more common in patients with unchanged facial sensation postoperatively. In conclusion, PRGR offers safe and reliable relief of pain in patients with trigeminal neuralgia. In spite of the high incidence of recurrence and of long-lasting dysaesthesias it is, in our opinion, the method of choice in the elderly, and particularly suitable for patients at high risk.

Adult↗

PubMed1993

Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.

Survival was analyzed in 173 patients with malignant gliomas to study the importance of possible pretreatment prognostic factors. Seventy-nine of these patients received preirradiation intra-arterial chemotherapy with BCNU combined with vincristine intravenously and procarbazine orally; the others received only postoperative whole-brain irradiation. To judge by univariate and multivariate analyses the most important pretreatment prognostic factors were histology, corticosteroid dependency, pretreatment performance status and frontal lobe location of the tumors. Patients with anaplastic astrocytoma, not corticosteroid-dependent, with pretreatment performance status of 0-2 and with a frontal lobe location of the tumor seemed to benefit most from preirradiation chemotherapy.

Adult↗

PubMed1992

Combined intra-arterial chemotherapy followed by radiation in astrocytomas.

Seventy-five patients harboring astrocytomas received 4 cycles of infra-ophthalmic carotid injections of BCNU, combined with vincristine intravenously and procarbazine orally. All of the patients thereafter, received radiation therapy. The five year survival was 73% for all patients. The age of the patients had no significant impact on survival. The treatment results were compared with the results of 57 patients with astrocytomas who were treated with surgery followed by radiation in the same period. These 57 patients had a 5 year survival of 45% with a five year survival in patients < or = 40 years and patients > 40 years of 70% and 22%, respectively (p < 0.05). In multivariate survival analysis of the BCNU group and radiation group together, treatment group and corticosteroid dependency were the only prognostic factors. No leukoencephalopathy was seen during the treatment or in the follow-up of the patients. We conclude that pre-radiation intra-arterial chemotherapy can be given without significant morbidity and produces an improvement in survival in patients older than 40 years.

Administration, Oral↗

PubMed1992

Pre-radiation chemotherapy in glioma patients with poor prognostic factors.

Nineteen patients in an age group from 56-67 years (mean age 62.5 years) with histologically verified glioblastoma multiforme were treated with chemotherapy consisting of two cycles of oral CCNU, intravenous vincristine and oral procarbazine prior to radiation therapy. Ten of the patients had stable disease, monitored by CT scan and neurological examination, and received whole brain radiation. The median survival was 12 months. Nine patients who had progressive disease during chemotherapy did not receive radiation treatment and were put on palliative treatment with dexamethasone. This group had a median survival of 3 months. The median survival in all of the 19 patients who entered the study was 9 months which was comparable to the survival of 56 patients with glioblastoma multiforme who, in a retrospective study, received post-operative radiotherapy. The most important factor predicting survival was steroid-dependency after surgery.

Aged↗

PubMed1992

High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression.

Twenty-eight consecutive patients were given high-dose dexamethasone (96 mg i.v. loading dose, decreasing doses to zero in 14 days) and radiotherapy for epidural spinal cord compression due to malignant disease. There were eight events classified as side effects of the dexamethasone treatment. Four of these were considered as serious (one fatal ulcer with haemorrhage, one rectal bleeding and one gastrointestinal perforation from undetermined origins, and one perforation of the sigmoid colon) giving a total rate of serious side effects of 14.3 percent. Due to the high incidence of serious side effects of the high dexamethasone dose, the regimen was abandoned in favor of a standard dexamethasone dose of 16 mg daily reduced to zero in 14 days. There were three events classified as side effects, but none were considered as serious in 38 consecutive patients receiving this dose. The differences both in total number of side effects and number of serious side effects are statistically significant. There was no significant difference in the number of ambulant patients in the group that received the high dexamethasone dose. We conclude that the high dexamethasone dose in our experience gives an unacceptably high incidence of serious side effects and we have therefore abandoned the regimen in favour of a more standard dexamethasone dose.

Aged↗

PubMed1992

Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.

Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine. Two milligrams of intravenous vincristine and 50 mg of oral procarbazine was also administered three times daily for 1 week in conjunction with each BCNU treatment. The response rate was 60% with a median survival for patients with astrocytomas, anaplastic astrocytomas, and glioblastomas of 32, 20, and 6.5 months, respectively. The median survival of the responding patients was 20 months, and the survival at 30 months was 45%. The survival in patients not responding to treatment was 5 months, reflecting the natural history of the tumor. There have been no deaths related to the treatment procedure. No incidents of severe or permanent eye complications or leukoencephalopathy were observed. Based on multivariate survival analysis, only patients with a good performance status who are not steroid dependent are candidates for this treatment.

Administration, Oral↗

PubMed1992

Primary malignant lymphoma of the brain. A report of 24 cases from the Norwegian Radium Hospital.

Between 1975 and 1987, 24 patients with primary central nervous system lymphoma were seen and treated at the Norwegian Radium Hospital. The overall median survival was 24 months. Patients with poor performance status (WHO 3-4) had a median survival of 3 months whereas patients with good performance status (WHO 0-2) had a median survival of 40 months (p < 0.0001). Patients who were not steroid-dependent after operation had a better survival than those patients who were steroid-dependent (p = 0.02). Nine patients were still living without evidence of disease at last follow-up, 18-130 months after the initial treatment.

Adolescent↗

PubMed1992

99mTc-hexamethylpropyleneamine oxime leukocyte scintigraphy and C-reactive protein levels in the differential diagnosis of brain abscesses.

The demonstration and accurate localization of intracerebral mass lesions are commonly performed with computerized tomography (CT), which often cannot determine the nature of the lesion. As an aid in the differential diagnosis between brain abscess and neoplasm, the authors have evaluated both 99mTc-hexamethylpropyleneamine oxime (99mTc-HMPAO) leukocyte scintigraphy and the serum C-reactive protein level. Of 23 patients with intracranial mass lesions, 22 individuals showed ring-like contrast enhancement on CT scans; the one exception was a patient treated for a meningioma who had a negative CT scan despite clinical suspicion of intra- or extracranial abscess. The final diagnosis was invariably established by microscopic examination of tissue specimens. In 10 patients the final diagnosis was brain abscess; the other 13 patients harbored a brain neoplasm (glioma in nine, astrocytoma in one, and metastasis in three). The 99mTc-HMPAO leukocyte scintigraphy detected all cases of abscess. There were no false-positive results. An elevated C-reactive protein level (> 13 mg/liter) was found in all but one patient with abscess and in three patients with neoplasm; two of these three patients had dental root infections which could account for the elevation of C-reactive protein. It is concluded that 99mTc-HMPAO leukocyte scintigraphy should be performed when there is a possibility that a brain abscess may exist. Any steroid treatment should be discontinued for 48 hours prior to leukocyte scintigraphy. Also, C-reactive protein determination should be performed and is useful even when steroids are given.

Adolescent↗

PubMed1991

[Treatment of spinal cord compression caused by malignant disease].

Patients suffering from metastatic spinal cord compression can be treated with decompressive surgery and/or radiotherapy. The best treatment regimen remains to be established. In the present paper we report our experience of a therapeutic regimen with main emphasis on radiotherapy, but where selected patients were treated with laminectomy followed by radiotherapy. 67 patients were treated during a two year period, 60 with radiotherapy as the sole treatment modality. The ambulation rate after treatment was 56.7%. Degree of loss of neurological function before treatment and tumour histology were prognostic factors for a successful outcome, defined as the patient's ability to walk after treatment. We emphasize the importance of starting treatment before development of advanced neurological deficits.

Adolescent↗

PubMed1991

Combined intra-arterial chemotherapy and irradiation of malignant gliomas.

Seventy-nine patients with malignant gliomas (19 anaplastic astrocytomas and 60 glioblastoma multiforme) received 4 cycles of infra-ophthalmic carotid injection of 160 mg carmustine, 2 mg vincristine IV and procarbazine orally 50 mg 3 times daily for 1 week, followed by whole-brain irradiation, with a midpoint dose of 54 Gy/6 weeks. Response, judged by CT-scan, was seen in 31 out of 57 evaluable patients with a median survival of 30 months and 40% survival at 3 years. In all patients who responded to the treatment, a tumour regression was seen on CT-scan after chemotherapy before irradiation. In the 26 patients with progressive disease under chemotherapy, the median survival was 5 months. None of the patients who had progressive disease during chemotherapy had benefit from irradiation. The most important prognostic factors were good pretreatment performance status, glucocorticoid dependency and age. Few serious side-effects of the angiographic procedure were seen. Leukoencephalopathy was not observed in this study.

Adolescent↗

PubMed1990

Intra-arterial BCNU in the treatment of recurrent medulloblastoma.

Two patients with recurrent medulloblastomas were treated with combined oral and intravenous chemotherapy followed by intra-arterial BCNU. The 7 days course of oral and intra-venous chemotherapy consisted of CCNU and Procarbazin orally and Vincristine intravenously (PCV), repeated after 6 weeks. Intra-arterial chemotherapy consisted of 4 cycles of BCNU. Both patients responded well to treatment, evaluated by CT scans. One of the patients died of a new local recurrence 6 months after initiation of chemotherapy, whereas the other patient remains well, without CT evidence of tumour 36 months after the start of the treatment. No serious adverse side-effects related to the treatment were seen.

Adult↗

PubMed1990

Reversible oedema and necrosis after irradiation of the brain. Diagnostic procedures and clinical manifestations.

One hundred and twelve patients with primary brain tumour were followed every 3 months during and after brain irradiation and chemotherapy with brain scanning, EEG and neurological examination. Early delayed radiation reactions were seen in 6 patients. The symptoms developed 2-8 months after irradiation and lasted for 2-3 months. Two types of reactions were observed. One mild form appeared after 2-3 months and was characterized by low-attenuated expansive areas within the irradiated volume, without contrast enhancement on CT scan. Severe reactions appeared in some patients after 6 months, with exacerbation of earlier clinical signs and contrast enhancing lesions on CT. Regression of the CT finding was seen after 3 months. Recognition of this syndrome is important, as a new neurosurgical procedure might cause lasting neurological sequelae in patients who otherwise would recover without treatment.

Adolescent↗

PubMed1989

[Intracranial stereotaxic external radiation using a linear accelerator].

The article describes a method making it possible to give high radiation doses to a localized volume of the brain while sparing normal surrounding brain tissue. The treatment consists of sending multiple narrow radiation beams from different directions to the volume of tissue to be treated by rotating the radiation source and the patient table in relation to each other. Mega-voltage radiation from a linear accelerator is used. A non-invasive stereotactic frame is mounted on the patient and a CT scan of the brain is performed to localize the center and extent of the tissue to be treated. The radiation treatment is then given by using the coordinates on the frame to assure that the center of rotation of the treatment table and the linear accelerator pass through the center of the volume of tissue. The method has been used to give radiation boosts after external radiation to brain tumours, and to treat patients with recurrent tumours. Small localized benign intracranial tumours and AV-malformations have also been treated.

Brain Neoplasms↗

PubMed1989

Localization of brain tumors with a simple scalp-mounted fiducial device. Technical note.

A method is described for marking the site of a tumor on the scalp based on information from computerized tomography (CT) scans. The technique employs a syrinx-shaped array of radiopaque catheters of varying length taped to the patient's scalp for visualization on the CT scan. Fiducial markings on the CT images allow the transfer of the tumor's location directly onto the scalp. The device can be placed anywhere on the scalp, including in a parasagittal position.

Brain Neoplasms↗

PubMed1989

Immunomagnetic separation of infiltrating T lymphocytes from brain tumors.

Tumor-infiltrating lymphocytes (TIL's) were isolated from human glioma biopsy specimens by immunomagnetic separation using T cell-specific monoclonal antibodies coupled to paramagnetic beads, and were expanded in culture with feeder cells and interleukin-2 (IL-2). The infiltrating cells from five of seven patients proliferated in culture. When tested after 2 to 3 weeks of culture, virtually all of the cells stained with antibodies against the CD2 and CD3 antigens. Most cells also expressed human leukocyte antigen class II molecules, while varying percentages of cells stained with antibodies against the IL-2 receptor and the CD4 and CD8 antigens. The cytotoxicity of the cultured TIL's against autologous and allogeneic glioma cells and the K562 and Daudi cell lines was measured and compared with that of lymphokine-activated killer (LAK) cells from the same patients. None of the TIL's showed significant cytotoxicity against these targets, whereas LAK cells lysed all of the targets.

Adult↗

PubMed1988

Human interleukin-2 activated cytotoxic cells kill autologous glioma cells in vitro.

We have cultured peripheral blood lymphocytes (PBL) from glioblastoma patients in recombinant interleukin-2 (IL-2) containing medium for a period of 5 days. The cytotoxicity of these cells was tested on 51Cr-labelled autologous dissociated glioblastoma cells which had not been cultured. Significant cytotoxicity against glioma cells was observed in seven out of nine cases. IL-2 activated PBL from normal donors were equally cytotoxic against these glioma cells. Autologous lymphocytes activated by phytohaemagglutinin were also lysed in most cases, and the erythroleukemia cell line K562 was highly susceptible to the cytotoxic capability of the IL-2 activated PBL. In cold target inhibition experiments, K562 inhibited the cytotoxicity against both autologous and allogenic glioma cells, and glioma cells inhibited the cytotoxicity against K562. Following immunomagnetic separation, the IL-2 activated cells demonstrated cytotoxicity against glioma cells, K562 cells, and PHA blasts in both the CD8+ and the CD8- subsets.

Adult↗